Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 220

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Prevalence of BRCA mutations in an unselected population of triple‐negative breast cancer

Open access
Hartman, Anne‐Renee, Kaldate, Rajesh R., Sailer, Lisa M., Painter, Lisa, Grier, Charles E., Endsley, Robbin R., Griffin, Marlena, Hamilton, Stephanie A., Frye, Cynthia A., Silberman, Mark A., Wenstrup, Richard J., Sandbach, John F.·2012·Cancer

Abstract

BACKGROUND: This study assessed BRCA1 and BRCA2 mutation prevalence in an unselected cohort of patients with triple‐negative breast cancer (BC). METHODS: One hundred ninety‐nine patients were enrolled. Triple negativity was defined as <1% estrogen and progesterone staining by immunohistochemistry and HER‐2/neu not overexpressed by fluorescence in situ hybridization. Having given consent, patients had BRCA1 and BRCA2 full sequencing and large rearrangement analysis. Mutation prevalence was assessed among the triple‐negative BC patients and the subset of patients without a family history of breast/ovarian cancer. Independent pathological review was completed on 50 patients. RESULTS: Twenty‐one deleterious BRCA mutations were identified—13 in BRCA1 and 8 in BRCA2 (prevalence, 10.6%). In 153 patients (76.9%) without significant family history (first‐degree or second‐degree relatives with BC aged <50 years or ovarian cancer at any age), 8 (5.2%) mutations were found. By using prior National Comprehensive Cancer Network (NCCN) guidelines recommending testing for triple‐negative BC patients aged <45 years, 4 of 21 mutations (19%) would have been missed. Two of 21 mutations (10%) would have been missed using updated NCCN guidelines recommending testing for triple‐negative BC patients aged <60 years. CONCLUSIONS: The observed mutation rate was significantly higher (P = .0005) than expected based on previously established prevalence tables among patients unselected for pathology. BRCA1 mutation prevalence was lower, and BRCA2 mutation prevalence was higher, than previously described. Additional mutation carriers would have met new NCCN testing guidelines, underscoring the value of the updated criteria. Study data suggest that by increasing the age limit to 65 years, all carriers would have been identified. Cancer 2011;. © 2011 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.26576

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 220

Metadata

Authors
Hartman, A., Kaldate, R. R., Sailer, L. M., Painter, L., Grier, C. E., Endsley, R. R., Griffin, M., Hamilton, S. A., Frye, C. A., Silberman, M. A., Wenstrup, R. J., & Sandbach, J. F.
Venue
Cancer
Publisher
Wiley
Published
2011-10-05
Volume
118
Issue
11
Pages
2787-2795
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W2110878808
Cited by
220
References
1
FWCI
7.49
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prevalence of BRCA mutations in an unselected population of triple‐negative breast cancer. https://app.cochat.ai/papers/10.1002/cncr.26576
The paper
Hartman, A., Kaldate, R. R., Sailer, L. M., Painter, L., Grier, C. E., Endsley, R. R., Griffin, M., Hamilton, S. A., Frye, C. A., Silberman, M. A., Wenstrup, R. J., & Sandbach, J. F. (2012). Prevalence of BRCA mutations in an unselected population of triple‐negative breast cancer. Cancer. https://doi.org/10.1002/cncr.26576

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.